Beta Bionics Mint (patch pump)

Mint is Beta Bionics' first tubeless patch pump — and it is not cleared. Its 510(k), filed as an alternate-controller-enabled (ACE) insulin pump, is under FDA review, and the company states plainly that Mint is "not available for sale."¹ Everything below comes from the company's own 21 May 2026 announcement and trade coverage of it; there are no published pivotal data and no independent performance testing. Treat every spec as a manufacturer claim about a device that does not yet exist on the market.

Why it matters: the algorithm, minus the tube. Beta Bionics' iLet Bionic Pancreas is defined by its dosing software — you enter only your body weight, never carb ratios — but it is a tubed pump you dose from its own touchscreen, and its phone app is view-only. Mint is designed to run the same interoperable automated glycemic controller (iAGC), the dosing engine the FDA has already authorized for the iLet, in a tubeless patch you drive from your phone.¹² If it ships as described, it removes the two things people most often hold against the iLet — the tubing and the missing phone bolus — while keeping the part they came for.

Form factor and wear. Mint is a two-piece patch: one reusable component and one disposable, an architecture Beta Bionics says is intended to limit environmental waste compared with a fully disposable pod. It never requires recharging and is waterproof for showering and swimming.² Size and weight have not been published, so how discreet it actually is on the body remains an open question.

Reservoir and wear time. The reservoir holds 200 units, with three days of wear plus an additional 12-hour grace period.² That is the same order of capacity and wear as today's leading disposable patch pods — competitive, but not the extended-wear, large-reservoir patch that a true artificial pancreas ultimately wants. The 12-hour grace period is a genuinely useful, if modest, touch: it means a pod change is not a hard cliff at 72 hours.

Which CGMs and algorithms it works with. Mint is designed to run Beta Bionics' iAGC with Dexcom G7, Dexcom G7 15 Day, and Abbott's FreeStyle Libre 3 Plus.² That is a closed commercial ecosystem: as with the iLet, it runs the company's own dosing software, and there is no support for DIY or open-source loops. The ACE-pump filing means Mint is being cleared as an interoperable building block — in principle drivable by other authorized interoperable controllers — but no such pairing has been announced, so the practical reality at launch would be one algorithm, three sensors.

Phone control. Full iOS and Android smartphone control is planned.² For a company whose current pump offers only a view-only app, this is the single biggest usability change in the product.

Reliability. Unknown, and honestly so. There is no clearance, no published pivotal trial, and no post-market record for this hardware. The dosing engine has evidence behind it; the patch, its cannula, its adhesive and its occlusion detection do not — not publicly, at any rate. That is what holds the reliability score down, and it should stay down until data appear.

Access and cost. There is none today: Mint cannot be bought anywhere. Beta Bionics says it will be available exclusively through the pharmacy channel, leveraging the market-access agreements it already holds for the iLet — which, if it holds, could make Mint easier to start on than a pump routed through durable-medical-equipment benefits.¹ No price, no coverage terms and no non-US plans have been disclosed.

What's coming, and how to read the date. On 21 May 2026 Beta Bionics said it expects to fully commercialize Mint by the end of Q2 2027, basing that timeline on the FDA's initial responses to the Mint ACE-pump 510(k) and on progress scaling manufacturing — explicitly "subject to regulatory clearance by the FDA."¹ Mint was also named among the next-generation pumps in development in trade coverage of ADA 2026, with launch expected in 2027.³ An initial FDA response is not a clearance, and a commercialization target is not an approval date. Until the 510(k) clears, this record stays in the pipeline.

References

1. Beta Bionics. Beta Bionics Updates Commercialization Timeline Expectations for Mint, its Patch Pump in Development (21 May 2026; issued via GlobeNewswire and filed as an exhibit to an SEC 8-K). Mint is "not available for sale"; its ACE-pump 510(k) is under FDA review; full commercialization expected by the end of Q2 2027 "subject to regulatory clearance by the FDA", based on the FDA's initial responses to the application; distribution planned exclusively through the pharmacy channel. https://www.globenewswire.com/news-release/2026/05/21/3299712/0/en/beta-bionics-updates-commercialization-timeline-expectations-for-mint-its-patch-pump-in-development.html ↩ ↩² ↩³ ↩⁴

2. StockTitan. Beta Bionics Updates Commercialization Timeline Expectations for Mint — wire carry of the 21 May 2026 company announcement, source of the device specifications: two-piece reusable and disposable architecture designed to limit environmental waste; 200-unit insulin reservoir; three days of wear time plus an additional 12-hour grace period; iOS and Android smartphone controlled; never requires recharging; waterproof for showering and swimming; runs the company's FDA-authorized interoperable automated glycemic controller (iAGC) with Dexcom G7, Dexcom G7 15 Day and Abbott's FreeStyle Libre 3 Plus. Manufacturer claims. https://www.stocktitan.net/news/BBNX/beta-bionics-updates-commercialization-timeline-expectations-for-fszqy6d893vw.html ↩ ↩² ↩³ ↩⁴ ↩⁵

3. Drug Delivery Business. The biggest diabetes tech news out of ADA 2026 — lists Mint among next-generation patch pumps in development, with launch expected in 2027. https://www.drugdeliverybusiness.com/biggest-diabetes-tech-news-ada-2026/ ↩